Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech, Inc. announced a license agreement with Dr. Reddy’s Laboratories for HLX15, a recombinant anti-CD38 human monoclonal antibody injection. This agreement grants Dr. Reddy’s exclusive rights to develop, manufacture, and commercialize HLX15 in the U.S. and 42 European countries. The deal includes upfront and milestone payments totaling up to $131.6 million, along with royalties on net sales, potentially enhancing Henlius’s market position and impacting stakeholders through expanded commercial opportunities.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of biopharmaceutical products. The company specializes in monoclonal antibody therapies, targeting various diseases, and aims to expand its market presence in global territories.
YTD Price Performance: -24.22%
Average Trading Volume: 718,435
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$9.76B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.